Melatonin, secreted by the pineal gland, is primarily known for its role in regulating sleep patterns. However, its influence extends beyond mere sleep enhancement. It possesses antioxidant properties and has been explored for its potential anti-cancer effects. This led researchers to consider whether melatonin could significantly alleviate symptoms faced by older cancer patients, including fatigue, anxiety, and depression—common outcomes in this demographic.

In the study, participants were carefully selected to represent a diverse cohort of older adults suffering from advanced forms of cancer. This demographic is particularly vulnerable due to the complex interplay of aging and cancer-related challenges, making their quality of life a crucial focal point for intervention strategies. By focusing on this specific group, the researchers aimed to contribute significantly to the body of knowledge surrounding supportive therapies in oncology.

One of the key aspects of the research design was its randomized controlled nature, which is considered the gold standard in clinical trials. This method reduces bias by randomly assigning participants to either a melatonin supplementation group or a placebo group. This allows for a more accurate assessment of the outcomes, as it minimizes the placebo effect—where participants may experience perceived improvements simply because they believe they are receiving treatment.

While the primary focus was on quality of life, the researchers also measured various secondary outcomes, including sleep quality, anxiety levels, and overall physical functioning. These parameters are critical for understanding the holistic impact of melatonin on the daily lives of participants. Advanced cancer patients often report poor sleep quality, so evaluating melatonin’s effect in this area was particularly pertinent.

Intriguingly, the findings from this trial indicated that participants who received melatonin reported notable improvements in their quality of life as compared to those who received the placebo. Respondents based their evaluations on a series of standardized questionnaires designed to capture various facets of their lived experiences. Many expressed feelings of increased energy and a more positive mood, which can significantly enhance their ability to cope with illness.

The results also indicated improvements in sleep patterns, with participants reporting fewer instances of insomnia and disturbances during the night. Sleep, as vital to health and recovery, is often compromised in patients dealing with the stresses of cancer treatment. The positive changes observed in sleep quality provided compelling evidence for melatonin’s potential benefits in this context.

Moreover, the researchers highlighted the safety profile of melatonin, noting that the supplement was well-tolerated among older adults. Adverse effects were minimal, reinforcing the notion that melatonin may serve as a viable adjunctive therapy in managing the multifaceted symptoms experienced by patients with advanced cancer. Its ease of use, coupled with a favorable safety profile, positions melatonin as an appealing option for clinicians seeking to improve their patients’ quality of life.

It is important to acknowledge the complexities surrounding pain management and the psychological dimensions of living with cancer. Many participants noted a reduction in anxiety levels, which correlated with their overall sense of well-being. This finding points towards the necessity of considering both physical and psychological aspects when addressing the needs of cancer patients. Melatonin may offer a multifaceted approach by not only addressing sleep issues but also impacting mood positively.

As discussions around integrative oncology continue to evolve, studies like this highlight the need for further exploration of non-pharmaceutical interventions. The growing interest in complementary therapies underscores the importance of finding solutions that can work alongside conventional treatments. Melatonin’s potential role in this landscape cannot be overlooked, as it aligns with the desires of many patients looking for holistic approaches to managing their health.

The implications of this research extend beyond individual patients, translating into broader discussions within the medical community on how best to support aging populations facing advanced cancer diagnoses. As society grapples with an increasing number of older adults diagnosed with cancer, healthcare professionals must evaluate innovative treatment modalities that enhance quality of life objectives.

Healthcare systems may also find value in integrating findings from this trial into patient care protocols. By considering melatonin as a supportive therapy, clinicians can champion a more comprehensive approach to cancer care, ultimately improving the trajectory of aging patients facing life-altering diagnoses.

In conclusion, the findings from Ginzac et al. open the door to exciting possibilities in the realm of cancer care for older adults. As researchers continue to explore melatonin’s therapeutic potential, it is imperative that future studies not only validate these results but also expand upon them. Only through continued investigation can the healthcare community fully understand melatonin’s place in supportive cancer therapy, potentially changing the landscape of how we approach quality of life in advanced cancer patients.

As this field of research advances, it will be vital to monitor ongoing studies and gather insights that reflect real-world applications. The pursuit of improving quality of life for those undergoing cancer treatment remains a pressing concern, making the exploration of substances like melatonin both timely and necessary. The dialogue around melatonin as a supportive therapy is likely to gain momentum, emphasizing the essential role that research plays in uncovering new avenues for patient care.

With continued effort and investigation into melatonin and its broad-spectrum effects, the potential to transform how we support older cancer patients appears promising. The implications of this study resonate with the urgent need to personalize patient care, underscoring the importance of addressing both the physical and emotional dimensions of health in the face of advanced illness.

In summary, melatonin supplementation represents a significant step forward in the quest for enhanced quality of life for older patients with advanced cancer. Integrating this knowledge into clinical practice could pave the way for innovative therapeutic strategies that resonate with the needs of patients in their most vulnerable moments.

Subject of Research: Melatonin supplementation for quality of life in older patients with advanced cancer.

Article Title: Melatonin supplementation for quality of life in older patients with advanced cancer: a randomized controlled trial.

Article References:
Ginzac, A., Bourbouloux, E., Rivoirard, R. et al. Melatonin supplementation for quality of life in older patients with advanced cancer: a randomized controlled trial.
BMC Geriatr (2025). https://doi.org/10.1186/s12877-025-06899-1

Image Credits: AI Generated

DOI:

Keywords: Melatonin, advanced cancer, quality of life, randomized controlled trial, older patients.

Melatonin has been shown to exhibit antioxidant properties that play a vital role in protecting cellular structures from oxidative stress. The significance of oxidative stress in reproductive health cannot be overstated, as it is known to affect gamete quality and overall fertility. In both male and female reproductive systems, oxidative stress can lead to cellular damage, making melatonin’s protective function crucial for maintaining healthy reproductive cells. This has led researchers to explore melatonin as a potential therapeutic agent to counteract infertility caused by oxidative damage.

The recent study by Kumar et al. highlights the multifaceted roles of melatonin within the reproductive axis. The researchers delve into melatonin’s function in regulating ovarian function, including folliculogenesis and corpus luteum activity. Melatonin’s influence over hormonal balance is particularly notable; it aids in modulating the secretion of key reproductive hormones like estrogen and progesterone. By optimizing these hormonal interactions, melatonin can potentially enhance ovulatory function and improve fertility outcomes in women seeking to conceive.

Moreover, the implications of melatonin extend to men’s reproductive health as well. Sperm quality, characterized by motility, morphology, and count, is often adversely affected by environmental factors and lifestyle choices. Melatonin’s antioxidative properties contribute to improved sperm quality. The study presents compelling evidence suggesting that melatonin supplementation may mitigate infertility issues in men by augmenting sperm parameters. This dual benefit highlights melatonin’s potential as a holistic approach to enhancing reproductive health across genders.

Another critical avenue explored in the research involves the timing of melatonin supplementation. The circadian rhythm profoundly influences reproductive functions, and the timing of melatonin administration may play a significant role in optimizing its effects. Proper synchrony between melatonin levels and reproductive cycles is essential for harnessing its fertility-enhancing properties. This nuanced understanding underscores the importance of personalized approaches when considering melatonin as a fertility aid.

Furthermore, the study addresses the question of dosage and long-term applicability. While preliminary findings are encouraging, determining the appropriate dosage of melatonin for fertility enhancement remains essential. Additionally, studies investigating the long-term effects of melatonin supplementation on reproductive health are pivotal to balancing benefits against potential risks. As interest in melatonin continues to grow among those seeking assistance in conception, these factors will be critical to developing safe and effective treatment protocols.

The impact of external factors, such as stress and environmental toxins, on reproductive health is increasingly recognized. Melatonin’s capacity to mitigate these effects positions it as a valuable ally in maintaining reproductive health. The study draws attention to the increasing prevalence of infertility attributed to lifestyle and environmental changes, emphasizing the need for innovative interventions. As a natural supplement with minimal side effects, melatonin offers a promising alternative to traditional pharmacological approaches to addressing fertility issues.

While the potential applications of melatonin in reproductive health are exciting, it is essential to approach these findings with a balanced perspective. Ongoing research and clinical trials will be integral to differentiating between anecdotal evidence and scientifically validated conclusions. Comprehensive studies that incorporate diverse demographics and varying conditions will be necessary to establish standardized treatment guidelines for melatonin use in fertility enhancement.

In light of the burgeoning interest in melatonin’s role in reproductive health, public awareness is crucial. Understanding the science behind melatonin and its physiological effects can empower individuals seeking to improve their fertility. Educational initiatives addressing the benefits and limitations of melatonin supplementation can bridge the gap between scientific research and practical application, ensuring that individuals make informed decisions about their reproductive health journeys.

As society continues to navigate the complexities of fertility and family planning, the exploration of natural supplements like melatonin opens new avenues for research and treatment. The intersection of sleep science, reproductive health, and nutritional interventions presents a growing frontier for future investigations. Researchers are encouraged to explore the integrative role of lifestyle factors, including sleep quality, in synergizing the effects of melatonin and enhancing overall reproductive outcomes.

In conclusion, melatonin emerges as a promising candidate in the quest for improved fertility and reproductive health. The combination of its antioxidative properties, its role in hormonal regulation, and the potential for personalized supplementation pathways establishes melatonin as a subject of significant interest in reproductive medicine. As further studies elucidate its mechanisms and refine its applications, melatonin may indeed become a fundamental component of fertility enhancement strategies, paving the way for happier, healthier pregnancies.

While the journey ahead in advancing reproductive health strategies through melatonin is filled with promise, it is paramount for researchers and practitioners to proceed with rigor. The growing body of evidence alongside continued rigorous investigation will ultimately determine the extent of melatonin’s role in addressing fertility challenges in contemporary society.

Subject of Research: Melatonin’s role in fertility and reproductive health.

Article Title: Melatonin: A Silver Bullet for Fertility and Reproductive Health.

Article References:
Kumar, P., Sahil, Quasmi, M.N. et al. Melatonin: A Silver Bullet for Fertility and Reproductive Health. Reprod. Sci. (2025). https://doi.org/10.1007/s43032-025-01997-2

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s43032-025-01997-2

Keywords: Melatonin, fertility, reproductive health, oxidative stress, hormonal regulation, supplementation.

Diabetic foot ulcers are chronic wounds that arise as a complication of diabetes, stemming primarily from neuropathy and peripheral vascular disease. The challenge in treating these ulcers lies in their tendency to become infected and the slow rate at which they heal, often leading to severe complications, including the need for amputations. Traditional treatments focus on improving blood flow and controlling infection; however, they have limitations that necessitate the exploration of novel therapies. This study evaluates the effectiveness of melatonin delivered topically, seeking to find an effective solution that can accelerate healing processes.

The trial’s meticulous design ensured robust findings. Researchers enrolled a significant cohort of diabetic patients suffering from foot ulcers and randomly assigned them to receive either topical melatonin or a placebo. Furthermore, the double-blind nature of the trial guarantees that neither the participants nor the researchers knew who received the active treatment or placebo, thus minimizing bias. The primary outcome measured was the percentage reduction in ulcer area over a defined treatment period, along with secondary outcomes including adverse events and patient-reported outcomes regarding pain and overall comfort.

The results revealed that patients receiving the topical melatonin reported greater reductions in ulcer size compared to those in the control group. After the specified treatment duration, the healing rates were markedly higher among those treated with melatonin, and the product was well-tolerated with limited adverse effects reported. These findings align with existing literature suggesting the beneficial effects of melatonin beyond its hormonal functions, particularly its role in modulating inflammatory responses—a significant factor in wound healing.

Melatonin’s mechanisms of action are multifaceted. As an antioxidant, it may reduce oxidative stress in fibroblasts, which are crucial for tissue repair. Furthermore, melatonin has been proposed to enhance antioxidant enzyme activity, promote hydration of the wound bed, and modulate the immune response to prevent infection. Collectively, these properties position melatonin as not just a supplemental treatment, but potentially a key player in the complex biological dance of wound healing, particularly in the context of diabetes.

In an era where the medical community is constantly seeking integrative and holistic approaches to treatment, the introduction of topical melatonin could revolutionize diabetic foot ulcer management. By combining traditional methods, such as wound debridement and infection control, with innovative solutions like melatonin therapy, healthcare providers can offer a more comprehensive strategy that addresses not only the symptoms but the underlying complications of diabetic ulcers.

Moreover, patient quality of life must not be overlooked. Ulcers can cause significant physical pain and emotional distress, impacting daily activities and overall well-being. Improved healing rates translate into enhanced comfort and faster return to normal daily functions for patients. The implications of this study extend beyond mere clinical metrics; they touch on the lived experiences of those affected by diabetes and their journey toward healing.

Despite the positive outcomes detailed in the trial, it is essential to acknowledge the limitations of the study. The sample size, while significant, may still be insufficient to generalize to the broader diabetic population. As with any clinical research, further studies—including larger, multicentric trials—are needed to verify these promising results and to fully understand the optimal dosing regimens and long-term effects of melatonin in this population.

As the medical community digests the findings of this trial, one must consider the accessibility and cost-effectiveness of implementing melatonin therapy in various healthcare settings. Consideration of these factors will be crucial in determining how widely this treatment can be integrated into standard care practices for diabetic foot ulcers across different regions, particularly in lower-resource settings where diabetes care may be less robust.

In conclusion, the double-blind, randomized clinical trial spearheaded by Ahmadvash et al. provides an exciting glimpse into the future of diabetic foot ulcer management with the introduction of topical melatonin. As researchers and clinicians continue to explore this avenue, the hope is that a scalable and effective treatment option may soon be available to improve the lives of many suffering from this debilitating complication of diabetes, driving progress towards improved healthcare solutions.

Combining detailed research findings with patient-centric perspectives, this study not only offers hope for innovations in wound care but also exemplifies the ongoing efforts in the field of endocrinology and diabetes management to utilize synthetic and natural substances in therapeutic avenues.

Subject of Research: The safety and efficacy of topical melatonin in healing diabetic foot ulcers.

Article Title: Safety and efficacy of topical melatonin add-on in healing of diabetic foot ulcer: a double blind, randomized clinical trial.

Article References:

Ahmadvash, F., Gharabagh, L.H., Emami, S. et al. Safety and efficacy of topical melatonin add-on in healing of diabetic foot ulcer: a double blind, randomized clinical trial.
BMC Endocr Disord 25, 254 (2025). https://doi.org/10.1186/s12902-025-02057-1

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12902-025-02057-1

Keywords: melatonin, diabetic foot ulcer, healing, clinical trial, antioxidants, treatment.

Neonatal hypoxia-ischemia remains a major contributor to morbidity and mortality in newborns. The injury can lead to various neurological deficits, including cerebral palsy, cognitive impairments, and behavioral disorders. Traditional therapies have had limited success in preventing or repairing the damage that occurs during these critical incidents. Therefore, identifying effective neuroprotective agents is paramount. The combination therapy discussed in this study presents an innovative approach targeting the multifaceted nature of brain injuries caused by hypoxia-ischemia.

The role of melatonin as a neuroprotective agent has garnered increasing attention in recent years. Known primarily for regulating circadian rhythms, melatonin possesses antioxidant properties that can reduce oxidative stress, a significant contributor to neuronal cell death. Its ability to modulate inflammation and promote cell survival pathways further strengthens its candidacy as a treatment for conditions characterized by brain injury. This study builds on previous research indicating the substance’s therapeutic potential and explores it in tandem with URB447—a compound known for its neuroprotective characteristics.

URB447, a selective cannabinoid receptor agonist, has shown promise in several preclinical studies aimed at treating neurological disorders. The synergy between cannabinoids and melatonin could enhance the protective effects against hypoxic-ischemic injury. By targeting different pathways involved in neuroprotection, the combination therapy aims to create a multi-pronged defense against the cascade of detrimental processes triggered by oxygen deprivation in the brain.

In their experimental design, the research team employed animal models to simulate the effects of neonatal hypoxia-ischemia. They administered both melatonin and URB447 surrounding the induced brain injury to assess their effects on neurobehavioral outcomes and histopathological analyses. The methodology was rigorous, ensuring that the findings were credible and could lead to effective clinical applications. This comprehensive approach exemplifies the need for multi-faceted strategies in addressing complex neurological injuries.

Results from the study indicated a significant improvement in neurobehavioral outcomes in subjects treated with the combination therapy compared to control groups. Notable improvements in motor function and cognitive assessments suggested a protective influence resulting from the administration of melatonin and URB447. Furthermore, histological examinations revealed reduced neuronal damage and apoptosis, confirming the protective effects observed in vivo.

Understanding the underlying mechanisms is critical for future therapeutic applications. The research team meticulously explored the biochemical pathways impacted by the combination therapy. Melatonin’s antioxidative properties, combined with URB447’s anti-inflammatory effects, appeared to cooperate in reducing oxidative stress and minimizing neuroinflammation. Such findings underscore the importance of a targeted approach in developing effective treatments for neonatal brain injuries.

As the researchers delve deeper into the biochemical interactions of melatonin and URB447, they raise intriguing questions about the optimal dosages and timing of administration. These variables can significantly influence the efficacy of treatments in clinically relevant scenarios. Moreover, the findings highlight the necessity of further studies to evaluate the long-term effects of such therapies and their translation into human medicine.

Besides therapeutic implications, the study invites broader discussions regarding the importance of developing interdisciplinary collaborations in research. By intertwining insights from neurobiology, pharmacology, and clinical practice, the investigation reveals how collective efforts can drive innovation in treatment development. It also emphasizes the need for increased funding and support for research endeavors targeting neonatal brain injury, an area often overlooked amid more prevalent diseases.

As promising as these findings are, the road to clinical application is fraught with challenges. Regulatory hurdles, potential side effects, and individual variability in response to treatment will require thorough examination. Therefore, ongoing clinical trials and further preclinical studies are essential to validate these findings and refine treatment protocols. This step is crucial in moving from bench to bedside and ensuring that vulnerable newborns benefit from these advancements.

The implications of this research extend beyond simply treating hypoxia-ischemia. It invites the possibility of utilizing combination therapies as a broader strategy for various neurological conditions. As researchers strive for more effective treatments for neurological disorders, the potential of pairing existing medications with novel compounds remains a rich avenue for exploration.

In conclusion, the insights gained from this study illuminate a path toward innovative and effective treatments for neonatal hypoxia-ischemia, harnessing the neuroprotective powers of melatonin and URB447. As researchers continue to unearth the complexities of these compounds and their interactions, the hope is that future generations will have access to therapies that can safeguard cognitive development and enhance quality of life for those impacted by early life brain injuries. The potential for a brighter future in neuroprotection is on the horizon as we stand on the cusp of a new era in neonatal care.

This study serves as a testament to the persistent quest for knowledge and the relentless pursuit of solutions to one of the most challenging aspects of pediatric medicine. As we await further developments from this research, the foundation has been laid for future breakthroughs that could ultimately change the landscape of neonatal health interventions.

Subject of Research: Neuroprotective effects of combination therapy in neonatal hypoxia-ischemia.

Article Title: Neuroprotective effect of the combination therapy of melatonin and URB447 after neonatal hypoxia-ischemia.

Article References:

Chillida, M., Alvarez, F.J., de la Parte, B.H. et al. Neuroprotective effect of the combination therapy of melatonin and URB447 after neonatal hypoxia-ischemia.
BMC Complement Med Ther 25, 274 (2025). https://doi.org/10.1186/s12906-025-05021-7

Image Credits: AI Generated

DOI: 10.1186/s12906-025-05021-7

Keywords: Neuroprotection, neonatal hypoxia-ischemia, melatonin, URB447, combination therapy.

Melatonin has long been the subject of intense scientific scrutiny due to its multifaceted biological roles. Beyond its established function in circadian rhythm regulation, melatonin exhibits notable antioxidant and immunomodulatory properties that have fueled investigations into its potential anti-cancer effects. The study in question pursued this line of inquiry by focusing on TLR4, a critical component of the innate immune system that triggers inflammatory responses upon detecting molecular patterns associated with pathogens or cellular damage. By examining these pathways in an in vivo ovarian cancer model, the researchers aimed to understand whether melatonin could attenuate tumor-promoting inflammation, potentially opening new avenues for cancer therapy.

The TLR4 signaling network is intricate, engaging two primary adaptor molecules: MyD88 and TRIF. These molecules initiate distinct but complementary cascades activating transcription factors that drive pro-inflammatory gene expression. Aberrant activation of this system often contributes to a tumorigenic microenvironment, fostering cancer cell survival, proliferation, and metastasis. Targeting TLR4-mediated signaling, therefore, holds therapeutic promise, especially in malignancies like ovarian cancer, where inflammation plays a significant pathogenic role.

Originally, the study reported that melatonin administration in experimental models led to a significant suppression of TLR4-driven inflammatory signaling. This effect purportedly involved downregulation of MyD88-dependent pathways, responsible for rapid activation of NF-κB and pro-inflammatory cytokines, as well as modulation of TRIF-related signaling, which influences interferon responses and late-phase inflammatory genes. Through this dual inhibitory mechanism, melatonin was suggested to exert a protective influence, reducing tumor-associated inflammation and potentially hindering ovarian cancer progression.

The research was conducted primarily by a collaborative group of investigators affiliated with prominent Brazilian institutions, including UNESP, UENP, UFSCar, UNICAMP, and CEVAP. Their integrated expertise spanned anatomy, biology, pathology, and venom studies, providing a comprehensive approach to exploring cancer immunology. The multidisciplinary team leveraged sophisticated in vivo models to mimic ovarian tumor microenvironments, employing molecular assays to dissect the complex interplay between melatonin and TLR4 signaling components at the cellular level.

Despite the initially promising results and the excitement generated by the prospect of a novel anti-inflammatory therapeutic strategy, the article was formally retracted due to concerns related to data validity and reproducibility. Retractions, while often viewed negatively, play a crucial role in maintaining the integrity of scientific literature. They prompt the research community to exercise caution, re-examining conclusions and reinforcing the importance of rigorous methodology, especially when findings have significant clinical implications.

The implications of this retraction extend beyond the specific study; they highlight the challenges inherent in translating molecular signaling insights into therapeutic interventions. The intricate network of immune signaling pathways involved in cancer is susceptible to various biological variables, experimental conditions, and analytical interpretations. As such, unraveling the precise role of molecules like melatonin requires comprehensive validation across multiple independent models and laboratories to ensure robustness and clinical relevance.

Furthermore, the retraction shines a spotlight on the imperative for transparency in the scientific process. Detailed methodological reporting, open data sharing, and collaborative verification are instrumental in advancing knowledge and fostering trust. As the field of cancer immunotherapy evolves, balancing innovation with rigor remains paramount, ensuring that new therapies are not only promising but also safe and effective.

The initial hypothesis linking melatonin to TLR4 pathway modulation remains a compelling question that continues to inspire research. Melatonin’s ability to influence immune cell function and cytokine production positions it as a candidate for further investigation. Future studies might consider alternative experimental designs, diverse model systems, and advanced molecular techniques to clarify its role in cancer-related inflammation comprehensively.

In parallel, the broader scientific effort to map the signaling circuitry of the tumor microenvironment proceeds unabated. Understanding how innate immune receptors like TLR4 engage with endogenous and exogenous factors to drive tumorigenesis is fundamental to developing precision medicine strategies. Therapies that can fine-tune immune responses hold potential to complement existing treatments, improving outcomes for patients suffering from ovarian cancer and other malignancies.

The retraction also underscores the necessity of cautious optimism in cancer research. Breakthrough findings, especially those offering affordable and accessible interventions such as melatonin, generate hope among clinicians and patients alike. However, scientific advancement is often incremental, shaped by iterative experimentation, peer review, and ongoing validation.

Scientific journals and publishers play a pivotal role in this ecosystem by providing mechanisms for correction and dialogue. The transparent publication of retraction notices, such as the one issued by BMC Cancer, facilitates an open scientific discourse. It serves as a reminder of the community’s commitment to uphold exemplary standards even amid the pressures to produce impactful results.

In conclusion, while the retraction of the melatonin and TLR4 signaling study represents a setback, it simultaneously reinforces the dynamic, self-correcting nature of science. The quest to harness immunological pathways for cancer therapy remains an active and critical field of inquiry. Researchers worldwide continue to unravel the molecular complexities of inflammation-associated cancers, employing innovative approaches and collaborations to deliver transformative treatments. The evolving narrative of melatonin’s role in ovarian cancer is emblematic of this journey—a testament to perseverance, intellectual honesty, and the relentless pursuit of truth in science.

Subject of Research: Melatonin’s modulation of TLR4-mediated inflammatory responses in ovarian cancer models.

Article Title: Retraction Note: Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.

Article References:
Chuffa, L.G.A., Fioruci-Fontanelli, B.A., Mendes, L.O. et al. Retraction Note: Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer. BMC Cancer 25, 876 (2025). https://doi.org/10.1186/s12885-025-14297-4

Image Credits: Scienmag.com